The Toxin Head-to-Head ChallengeFor answers, Dermatology Times and Cosmetic Surgery Times developed an online survey for readers. The activity presented images from 6 patients who were photographed on the day of their injection and 30 days after treatment with either Xeomin® (incobotulinumtoxinA, Merz Pharmaceuticals) or Botox® (onabotulinumtoxinA, Allergan).
ABCs and 123s of ona-, abo- and incobotulinumtoxinA
ABCs and 123s of ona-, abo- and incobotulinumtoxinAA recently published stepwise approach to treating wrinkles provides a template for achieving safe, effective results with FDA-approved neurotoxins.
Xeomin vs Botox: Head-to-head study resultsThis is the first randomized, prospective, double-blinded, parallel-group study to compare the neurotoxins head to head.
Botulinum toxin market grows along with senior segment
Botulinum toxin market grows along with senior segmentCurrent botulinum toxin products are more similar than different and can be effectively used for many purposes beyond facial lines and wrinkles.
Botox vs Xeomin: Study results are inThis is the first prospective, split-face, randomized, double-blind study to address three types of facial wrinkles — glabellar lines, crow’s feet and forehead lines — using a 1:1-dose ratio.
Merz to acquire Ulthera for $600MMerz has entered a definitive merger agreement to acquire energy device maker Ulthera in a deal that could be valued at more than $600 million.
Reconstitution is key to optimizing neurotoxin results
Reconstitution is key to optimizing neurotoxin resultsSuboptimal reconstitution of botulinum toxin type A preparations can diminish the efficacy of neuromodulators for cosmetic use.
Epinephrine may prolong neuromodulator resultsMixing neuromodulators with epinephrine may give patients the longer-lasting results they seek, according to an expert at Cosmetic Surgery Forum. This combination, however, may not prove beneficial for everyone.
Navigating neurotoxins’ differencesWe now have three neurotoxins in our marketplace. Do you feel that these neurotoxins differ, and if so, how? An expert panel addresses the topic at the 2013 Vegas Cosmetic Surgery and Aesthetic Dermatology meeting.
Merz to acquire NeocutisMerz Pharma Group has entered into an agreement with Neocutis to acquire its cosmetic, prescription and over-the-counter skincare products.